Drugs.com - Monthly Update August 2025
Welcome to the August 2025 edition of Drugs.com monthly update. This month, we delve into key FDA approvals that offer new hope for patients and health care providers alike. This episode uses AI tools to help with formatting, organization, and narration. All content has been reviewed by a senior editorial pharmacist.
Narrator:Today, we're unpacking breakthroughs from Wegovy, now indicated for metabolic dysfunction associated steatohepatitis, (or MASH), to Ajovy's expanded use for pediatric migraine prevention, and several more significant developments.
Narrator:We begin with a major development for liver health. Wegovy, spelled W E G O V Y, has been granted accelerated approval by the FDA for treating non cirrhotic metabolic dysfunction associated steatohepatitis (or MASH) in adults. MASH, a progressive liver disease, can lead to serious complications like liver cancer if not managed properly. Wegovy, a GLP-1 receptor agonist, showed promising results in the ESSENCE trial, improving liver fibrosis and resolving steatohepatitis in a significant percentage of patients. It is administered as a weekly injection, offering an important tool for health care professionals and patients battling this silent but severe condition.
Narrator:As with any new therapy, it's vital to consider safety, with common side effects including gastrointestinal symptoms and a boxed warning for thyroid tumors.
Narrator:In pain management, we see a noteworthy approval with Tonmya, spelled T O N M Y A, for fibromyalgia. For over 15 years, patients have awaited a new FDA approved treatment for this complex chronic condition. Tonmya's novel sublingual formulation of cyclobenzaprine aims to tackle underlying sleep disturbances, a key component of fibromyalgia. Clinical trials revealed significant pain reduction with Tonmya compared to a placebo, offering patients hope for improved quality of life with reduced daytime drowsiness.
Narrator:However, like all medications, Tonmya comes with its own set of precautions, including potential serotonin syndrome and oral discomfort.
Narrator:Turning to pediatrics, there's significant news for migraine sufferers. The FDA now approves Ajovy, spelled A J O V Y, for preventing episodic migraines in children aged 6 to 17 years old who weigh 45 kg or more. This calcitonin gene related peptide antagonist has been a game changer for adults since 2018, and its pediatric approval marks a milestone for younger patients who endure the disabling pain of migraines, impacting their schooling and social lives. Ajovy offers a fresh option for clinicians with its favorable safety profile, though injection site reactions and allergic responses are considerations.
Narrator:We're also spotlighting Repatha, spelled R E P A T H A, with an expanded indication to manage elevated LDL cholesterol in adults at risk for major cardiovascular events, even those without established cardiovascular disease. This PCSK9 inhibitor can now be administered to a larger patient pool, promoting preventive care without the baggage of severe preexisting conditions. Administered subcutaneously, it's a potent addition to lifestyle modifications, though patients should be aware of possible hypersensitivity reactions.
Narrator:Finally, lung health advances with Brinsupri, spelled B R I N S U P R I, approved for non cystic fibrosis bronchiectasis. This oral therapy targets chronic airway inflammation, a burdensome aspect of this lung disease. Clinical trials highlighted Brinsupri's capacity to reduce flare ups, providing relief from persistent symptoms. Potential users should consider skin and gum related side effects.
Narrator:Thank you for tuning in to the Drugs.com Monthly Update Podcast, where staying informed means staying ahead in your field. We look forward to bringing you more updates next month. Until next time, know more, be sure.
